Enwave Corporation Stock
?
Your prediction
Pros and Cons of Enwave Corporation in the next few years
Pros
Cons
Performance of Enwave Corporation vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Enwave Corporation | 1.740% | -6.952% | -10.769% | 17.568% | -26.271% | -0.229% | -81.128% |
| Aurinia Pharmaceuticals Inc. | 0.740% | -3.135% | 2.414% | 64.888% | -7.090% | 51.367% | 8.637% |
| Spectral Medical Inc | -2.440% | 1.235% | 5.128% | 94.313% | 3.145% | 294.231% | 153.086% |
| Xenon Pharmaceuticals Inc. | 1.000% | 42.265% | 47.143% | 61.950% | 35.526% | 59.938% | - |
News
EnWave Reports 2026 First Quarter Consolidated Interim Financial Results
Vancouver, B.C., February 20th, 2026. EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") today reported the Company’s consolidated interim financial results for the first
EnWave Signs Royalty-Bearing License with Bowen Gumlu Grower’s Association of Australia
Vancouver, B.C., February 2nd, 2026, EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") today announced that the Company has signed a royalty-bearing commercial license
EnWave Reports 2025 Fourth Quarter and Annual 2025 Consolidated Financial Results
Vancouver, B.C., December 15th, 2025 / EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") today reported the Company’s consolidated interim financial results for the fourth

